Immunomedics (IMMU) Receives New U.S. Patent Covering IMMU-130

October 19, 2016 7:03 AM EDT

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Immunomedics, Inc., (Nasdaq: IMMU) announced the issuance of U.S. Patent 9,458,242 for additional claims under the patent family “Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity.” This new patent, which will expire in July 2033, covers the use of labetuzumab govitecan (IMMU-130), the Company’s second investigational antibody-drug conjugate (ADC) for solid cancer therapy.

Labetuzumab govitecan is composed of SN-38, the active metabolite of irinotecan, an FDA approved chemotherapy for colorectal cancer, linked to labetuzumab, the Company’s humanized antibody that targets the carcinoembryonic antigen (CEACAM5), which is expressed on colorectal and other solid cancers. This ADC, at the 10 mg/kg dose level, has been active in the therapy of patients with metastatic colorectal cancer who had failed multiple prior therapies, including irinotecan.

“We are very encouraged by the results with IMMU-130 from an open-label Phase 2 study, which has completed patient enrollment with patient follow-up continuing,” commented Cynthia L. Sullivan, President and Chief Executive Officer. “We have had an end-of-Phase 2 discussion with the FDA for a future registration pathway for this ADC. One Phase 3 study design under consideration includes evaluating IMMU-130 in patients with metastatic colorectal cancer who have received two or more prior therapies,” Ms. Sullivan added.

Also issued today was U.S. Patent 9,457,072 to IBC Pharmaceuticals, Inc., the Company’s majority-owned subsidiary, for additional claims under the patent family “Dock-and-Lock® (DNL®) vaccines for cancer therapy.” This new patent, which will expire in March 2026, concerns methods and compositions for creating anti-cancer vaccine complexes using the Company’s proprietary DNL® protein conjugation platform technology. These DNL® complexes have the ability to simultaneously bind to dendritic cells on one arm and to tumor markers on cancer cells using the other arm. In so doing, these anti-cancer vaccine DNL® complexes are designed to induce an immune response against their targeted cancer cells, which could inhibit the growth of, or eliminate, the cancer cells.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Litigation, Management Comments

Add Your Comment